These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20226481)

  • 21. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes.
    Tsukahara H; Sekine K; Uchiyama M; Kawakami H; Hata I; Todoroki Y; Hiraoka M; Kaji M; Yorifuji T; Momoi T; Yoshihara K; Beppu M; Mayumi M
    Pediatr Res; 2003 Sep; 54(3):419-24. PubMed ID: 12761359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
    Yoshida N; Okumura K; Aso Y
    Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Measurement of plasma pentosidine and the clinical significance in diagnosis of diabetic nephropathies].
    Sanaka T; Hosokawa T
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():373-8. PubMed ID: 15999737
    [No Abstract]   [Full Text] [Related]  

  • 24. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
    Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
    J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
    Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW
    Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.
    Beisswenger PJ; Moore LL; Brinck-Johnsen T; Curphey TJ
    J Clin Invest; 1993 Jul; 92(1):212-7. PubMed ID: 8325987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced glycation end-products and the progress of diabetic vascular complications.
    Jakus V; Rietbrock N
    Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
    Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
    Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia.
    Ueda Y; Miyata T; Hashimoto T; Yamada H; Izuhara Y; Sakai H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Apr; 245(3):785-90. PubMed ID: 9588192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.
    Koyama Y; Takeishi Y; Arimoto T; Niizeki T; Shishido T; Takahashi H; Nozaki N; Hirono O; Tsunoda Y; Nitobe J; Watanabe T; Kubota I
    J Card Fail; 2007 Apr; 13(3):199-206. PubMed ID: 17448417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentosidine plasma levels and relation with metabolic control in diabetic patients.
    Lapolla A; Reitano R; Baccarin L; Sartore G; Plebani M; Fedele D
    Horm Metab Res; 2005 Apr; 37(4):252-6. PubMed ID: 15952087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia.
    Sell DR; Nagaraj RH; Grandhee SK; Odetti P; Lapolla A; Fogarty J; Monnier VM
    Diabetes Metab Rev; 1991 Dec; 7(4):239-51. PubMed ID: 1813279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
    Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
    Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency.
    Schiel R; Franke S; Busch M; Müller A; Fleck C; Müller UA; Braun A; Stein G
    Eur J Med Res; 2003 Jul; 8(7):283-91. PubMed ID: 12911864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
    Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
    Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
    Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
    J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease.
    Kerkeni M; Weiss IS; Jaisson S; Dandana A; Addad F; Gillery P; Hammami M
    Thromb Res; 2014 Sep; 134(3):633-8. PubMed ID: 25065554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients.
    Taki K; Takayama F; Tsuruta Y; Niwa T
    Kidney Int; 2006 Jul; 70(1):218-24. PubMed ID: 16723988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
    Forbes JM; Thorpe SR; Thallas-Bonke V; Pete J; Thomas MC; Deemer ER; Bassal S; El-Osta A; Long DM; Panagiotopoulos S; Jerums G; Osicka TM; Cooper ME
    J Am Soc Nephrol; 2005 Aug; 16(8):2363-72. PubMed ID: 15930093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.